1 334

Cited 34 times in

CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy

Authors
 WOONG SUB KOOM  ;  JINSIL SEONG  ;  YONG BAE KIM  ;  HAE OK PYUN  ;  SI YOUNG SONG 
Citation
 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.73(4) : 1148-1154, 2009 
Journal Title
 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 
ISSN
 0360-3016 
Issue Date
2009
MeSH
Adult ; Aged ; Analysis of Variance ; CA-19-9 Antigen/blood* ; Combined Modality Therapy/methods ; Dose-Response Relationship, Radiation ; Female ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/blood* ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/radiotherapy ; Prognosis ; Remission Induction ; Retrospective Studies ; Survival Rate
Keywords
Pancreatic cancer ; CA 19-9 ; Chemoradiotherapy ; Tumor response ; Survival
Abstract
PURPOSE: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. METHODS AND MATERIALS: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. RESULTS: Seventeen patients (25%) had a 50% or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline <or=40% (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. CONCLUSIONS: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline <or=40% may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy.
Full Text
http://www.sciencedirect.com/science/article/pii/S0360301608024620
DOI
10.1016/j.ijrobp.2008.06.1483
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Koom, Woong Sub(금웅섭) ORCID logo https://orcid.org/0000-0002-9435-7750
Kim, Yong Bae(김용배) ORCID logo https://orcid.org/0000-0001-7573-6862
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103554
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links